|Articles|November 1, 2001

Public nursing homes provide better care

Nonprofit nursing homes provide better care and more nursing care than investor-owned homes, according to a survey of over 13,500 homes nationwide.

Nonprofit nursing homes provide better care and more nursing care than investor-owned homes, according to a survey of over 13,500 homes nationwide. According to the study, published in The American Journal of Public Health (vol. 91, no. 9), private facilities averaged 5.89 deficiencies per home, 46.5% higher than nonprofit homes and 43% higher than public homes.

In addition, the study found that:


• Numbers of licensed nursing hours per patient day at private facilities were 31.7% lower than at nonprofit facilities, and 22% lower than at public homes.


• Nursing aide hours at private homes were 11.9% less than at nonprofit facilities and 16% less than at public homes.


• Rates of severe deficiencies at investor-owned facilities were 40.5% higher than at nonprofit homes and 35.8% higher than at public homes.

Said the authors, "Our results suggest that investor-owned nursing homes deliver lower-quality care than do nonprofit or public facilities. Moreover, investor-owned facilities usually are part of a chain, and chain ownership per se is associated with a further decrement in quality."

The authors concluded: "The most obvious explanation for our findings is that profit-seeking diverts funds and focus from clinical care." PR


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.